U.S. License Holder:
Samsung Bioepis / Biogen
Date of License:
BYOOVIZ (ranibizumab-nuna), a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:
Neovascular (Wet) Age-Related Macular Degeneration (AMD);
Macular Edema Following Retinal Vein Occlusion (RVO);
Myopic Choroidal Neovascularization (mCNV).
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In The E.U.
Byooviz (Samsung Bioepis / Biogen) (August-2021)